Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Clinical trial NCT03236428 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03236428
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-24
- Primary completion
- 2021-10-04
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.